In Q3 of fiscal 2013, the quarter ended Sep 30, 2013, Tanke Biosciences Corp generated $1.6 million of cash from operations, up 3.8% from the same quarter a year earlier. It spent $1.1 million on capital expenditures. That left free cash flow of $538,076.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2013
|
Q3 FY2013
Sep 30, 2013
|
Q2 FY2013
Jun 30, 2013
|
Q1 FY2013
Mar 31, 2013
|
Q4 FY2012
Dec 31, 2012
|
Q3 FY2012
Sep 30, 2012
|
Q2 FY2012
Jun 30, 2012
|
Q1 FY2012
Mar 31, 2012
|
Q4 FY2011
Dec 31, 2011
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Depreciation and amortization |
1
+27.0%
|
0
+52.3%
|
0
+71.0%
|
0
+45.3%
|
0
-15.4%
|
0
+155.8%
|
0
+91.1%
|
0
|
0
|
| Stock-based compensation |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
|
—
|
| Operating cash flow |
-4
-179.8%
|
2
+3.8%
|
-0
-107.6%
|
-0
-119.9%
|
-5
-785.6%
|
2
+5889.2%
|
2
-39.0%
|
1
|
1
|
| Investing | |||||||||
| Capital expenditures |
2
+143.1%
|
1
+160.9%
|
1
+215.1%
|
1
+285.3%
|
0
-74.8%
|
0
+9.3%
|
0
+94.4%
|
0
|
0
|
| Investing cash flow |
-2
+37.1%
|
-1
-174.4%
|
-1
+25.5%
|
-1
-96.2%
|
0
+105.4%
|
-0
+50.3%
|
-1
-13.3%
|
-0
|
-2
|
| Financing | |||||||||
| Debt issued |
—
|
0
|
0
|
1
|
—
|
—
|
—
|
—
|
—
|
| Debt repaid |
—
|
0
|
0
|
1
|
—
|
—
|
—
|
—
|
—
|
| Financing cash flow |
-0
-116.3%
|
-0
-436.8%
|
-0
-111.4%
|
0
+175.5%
|
0
+116.2%
|
-0
|
1
-77.8%
|
-0
|
-0
|
| Change in cash | |||||||||
| Effect of exchange rate |
0
+118.0%
|
0
+139.7%
|
0
-21.2%
|
0
-69.5%
|
-0
+92.3%
|
-0
-122.0%
|
0
+184.7%
|
0
|
-1
|
| Free cash flow |
-6
-273.3%
|
1
-52.8%
|
-1
-147.6%
|
-1
-368.9%
|
-5
-1100.2%
|
1
+425.4%
|
2
-43.7%
|
0
|
1
|
| Per share | |||||||||
| Free cash flow per share |
—
|
—
|
—
|
—
|
—
|
0.09
+425.4%
|
0.12
-43.7%
|
0.02
|
0.04
|
| Ratios | |||||||||
| Free cash flow margin |
-26.68%
|
8.91%
|
-13.42%
|
-18.18%
|
-75.85%
|
11.51%
|
21.17%
|
6.94%
|
7.62%
|
| Capital expenditures to revenue |
10.84%
|
17.77%
|
11.00%
|
16.01%
|
0.84%
|
4.15%
|
2.62%
|
4.26%
|
3.37%
|
| Stock-based compensation to revenue |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.00%
|
—
|
| Cash conversion |
—
|
—
|
-1.14x
|
—
|
—
|
1.60x
|
6.49x
|
—
|
0.37x
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Grain Mill Products (SIC 2040)
- Listed as
- TNBI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Pearl River New City Guangzhou, China
- SEC CIK
- 1452011
- Former names
- GREYHOUND COMMISSARY, INC. (until Feb 3, 2011)
Other Grain Mill Products companies
- General Mills Inc GIS
- Ingredion Inc INGR
- Post Holdings, Inc. POST
- Freshpet, Inc. FRPT
- Forafric Global PLC AFRI
Source: SEC EDGAR filings. This is company-reported data, not investment advice.